RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+10.77%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$4.58B
AUM Growth
+$4.58B
(-2.1%)
Cap. Flow
+$43.2M
Cap. Flow
% of AUM
0.94%
Top 10 Holdings %
Top 10 Hldgs %
23.53%
Holding
172
New
18
Increased
60
Reduced
32
Closed
20
Top Buys
| 1 |
Immunocore
IMCR
|
$97.6M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$73M |
| 3 |
Bolt Biotherapeutics
BOLT
|
$51.3M |
| 4 |
Cullinan Oncology
CGEM
|
$44.8M |
| 5 |
AstraZeneca
AZN
|
$32.3M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$54.5M |
| 2 |
UnitedHealth
UNH
|
$48.4M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$47.9M |
| 4 |
Centene
CNC
|
$43.8M |
| 5 |
Immunovant
IMVT
|
$41.2M |
Sector Composition
| 1 | Healthcare | 93.74% |
| 2 | Consumer Staples | 1.75% |
| 3 | Industrials | 0.62% |
| 4 | Financials | 0.12% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Shattuck Labs
STTK
$47M
| $11.4M | 0.25% | 388,499 -100,501 | -21% | -$2.94M |
|
102
CONMED
CNMD
$1.68B
| $11.1M | 0.24% | 85,085 +7,085 | +9% | +$925K |
|
103
Protara Therapeutics
TARA
$120M
| $10.9M | 0.24% | 689,942 +46,742 | +7% | +$736K |
|
104
FibroGen
FGEN
$47.8M
| $10.9M | 0.24% | 312,687 +3,300 | +1% | +$115K |
|
|
TBIO
105
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $10.7M | 0.23% | 649,900 +6,400 | +1% | +$106K |
|
|
NGM
106
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $10.6M | 0.23% | 364,800 +4,300 | +1% | +$125K |
|
|
RXDX
107
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $10.5M | 0.23% | +574,858 | New | +$10.5M |
|
108
Compugen
CGEN
$132M
| $10.5M | 0.23% | 1,219,488 +85,888 | +8% | +$738K |
|
|
KDNY
109
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $10.5M | 0.23% | 673,049 +4,200 | +0.6% | +$65.3K |
|
110
Xenon Pharmaceuticals
XENE
$2.98B
| $10.2M | 0.22% | 572,500 +57,500 | +11% | +$1.03M |
|
|
KNTE
111
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $10.2M | 0.22% | 326,386 +1,700 | +0.5% | +$53K |
|
|
FUSN
112
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $10.2M | 0.22% | 948,327 | – | – |
|
113
Aurinia Pharmaceuticals
AUPH
$1.58B
| $10.1M | 0.22% | 781,569 +7,900 | +1% | +$103K |
|
114
Amicus Therapeutics
FOLD
$2.34B
| $10M | 0.22% | 1,012,506 -16,494 | -2% | -$163K |
|
|
OHPAU
115
DELISTED
Orion Acquisition Corp. Unit
OHPAU
| $10M | 0.22% | +1,000,000 | New | +$10M |
|
116
Design Therapeutics
DSGN
$315M
| $9.79M | 0.21% | +327,250 | New | +$9.79M |
|
117
Nurix Therapeutics
NRIX
$714M
| $9.67M | 0.21% | 310,950 +53,700 | +21% | +$1.67M |
|
118
Legend Biotech
LEGN
$6.41B
| $9.07M | 0.2% | 312,618 +3,200 | +1% | +$92.9K |
|
119
Relay Therapeutics
RLAY
$619M
| $8.72M | 0.19% | 252,127 -159,873 | -39% | -$5.53M |
|
|
ADAP
120
Adaptimmune Therapeutics
ADAP
$15.6M
| $8.2M | 0.18% | 1,545,000 | – | – |
|
121
West Pharmaceutical
WST
$17.8B
| $8.03M | 0.18% | 28,500 | – | – |
|
|
BCEL
122
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $6.96M | 0.15% | 453,930 +2,700 | +0.6% | +$41.4K |
|
|
CHMA
123
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $6.81M | 0.15% | 2,174,583 +38,069 | +2% | +$119K |
|
|
TRIL
124
DELISTED
Trillium Therapeutics Inc.
TRIL
| $6.67M | 0.15% | 620,800 +2,300 | +0.4% | +$24.7K |
|
125
Talphera
TLPH
$11.1M
| $6.44M | 0.14% | 3,785,457 +3,000 | +0.1% | +$5.1K |
|